Christopher Lemke
About Christopher Lemke
Christopher Lemke serves as the Director of Structural Biology at the Broad Institute of MIT and Harvard, where he has worked since 2022. He possesses over twenty years of experience in industrial drug discovery and has a strong academic background in biochemistry and genetics.
Work at Broad Institute
Christopher Lemke serves as the Director of Structural Biology at the Broad Institute of MIT and Harvard. He has held this position since 2022, contributing to the advancement of structural biology research in Cambridge, Massachusetts. In this role, he has established and directly managed a highly functional structural biology team, focusing on enabling projects through techniques such as protein crystallography and cryo-electron microscopy (cryo-EM). His leadership aims to support innovative research initiatives within the institute.
Education and Expertise
Christopher Lemke has an extensive academic background in the life sciences. He earned a Bachelor of Science in Genetics and Biochemistry from the University of Guelph from 1992 to 1996. He then pursued a Doctor of Philosophy in Biochemistry at the University of Toronto, completing his studies from 1996 to 2002. His educational journey has equipped him with a comprehensive understanding of protein science, molecular modeling, medicinal chemistry, and pharmacology.
Background
Christopher Lemke has over twenty years of experience in the pharmaceutical industry, specifically in supporting drug discovery processes. His expertise spans from target assessments to IND enabling studies. He has also gained indirect management experience with teams focused on protein science, computer-assisted drug design (CADD), and antibody discovery. This diverse background has contributed to his proficiency in structurally enabling projects and advancing pharmaceutical research.
Achievements in Research
Christopher Lemke has a solid record of patents and publications in pharmaceutical research. His work has contributed to advancements in the field, particularly in structural biology and drug discovery. His proficiency in techniques such as protein crystallography and cryo-EM has enabled significant progress in various research projects, showcasing his commitment to innovation in the pharmaceutical sciences.